Lola Rahib and Patrick van der Valk explain how Cancer Commons and xCures are using real-world data to improve care for future patients.
Dr. Eugene Koay is leading a platform trial, for a more nimble way to adapt to participants’ response to treatments being tested.
Researchers are conducting a phase 0 study of a new drug that may cause inflammation to stimulate immune system against cancer.
Researchers are testing a new drug that better-allows chemotherapy to penetrate the tumor microenvironment of pancreatic cancer.
Dr. Kim A. Reiss is leading a study of the PARP inhibitor olaparib to delay or prevent a recurrence of surgically removed pancreatic cancer.
A clinical trial looks at whether molecular subtyping of tumors is effective in determining the best pancreatic cancer treatment.
Dr. Elizabeth Jaffee explains the importance of Lustgarten’s Clinical Accelerator Initiative to speed up the time from bench to trial.
Researchers are testing whether a vaccine can heighten the body’s immune response to pancreatic cancer after surgical removal of the tumor.